2-甲氧基-5-硝基-6-甲基吡啶 | 5467-69-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 2-甲氧基-5-硝基-6-甲基吡啶
• 中文别名: 6-甲氧基-2-甲基-3-硝基吡啶；6-甲氧基-3-硝基-2-甲基吡啶；2-甲基-3-硝基-6-甲氧基吡啶；2-甲基-6-甲氧基-3-硝基吡啶
• 英文名称: 6-methoxy-2-methyl-3-nitropyridine
• 英文别名: 6-methoxy-3-nitro-2-picoline；6-methoxy-2-methyl-3-nitro-pyridine；6-Methoxy-2-methyl-3-nitro-pyridin；2-methyl-6-(methyloxy)-3-nitropyridine；2-methoxy-5-nitro-6-methylpyridine；2-Methoxy-5-nitro-6-methylpyridin
• CAS: 5467-69-6
• 化学式: C₇H₈N₂O₃
• mdl: MFCD03095076
• 分子量: 168.152
• InChiKey: GSJQJZOENXJWIP-UHFFFAOYSA-N

物化性质

• 熔点：
  104-108 ºC
• 沸点：
  261.1±35.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  67.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methoxy-5-nitro-6-picoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methoxy-5-nitro-6-picoline
CAS number: 5467-69-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8N2O3
Molecular weight: 168.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲氧基-5-硝基-6-甲基吡啶 在 palladium 10% on activated carbon aluminum (III) chloride 、 sodium tetrahydroborate 、 乙醇 、 氢气 、 氢化钾 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 20.0 ℃ 、275.8 kPa 条件下， 反应 56.08h， 生成 3-hydroxy-6-methoxy-3,4-dihydro-1H-[1,5]naphthyridin-2-one
  参考文献：
  名称：

  [EN] INHIBITORS OF JANUS KINASES
  [FR] INHIBITEURS DE JANUS KINASES

  摘要：

  本发明提供了抑制四种已知的哺乳动物JAK激酶（JAK1、JAK2、JAK3和TYK2）和PDK1的化合物。该发明还提供了包含这种抑制化合物的组合物，并通过向需要治疗骨髓增生性疾病或癌症的患者施用该化合物来抑制JAK1、JAK2、JAK3、TYK2和PDK1的活性的方法。

  公开号：

  WO2009155156A1
• 作为产物：
  描述：

  三甲基环三硼氧烷 在 四(三苯基膦)钯 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 22.25h， 生成 2-甲氧基-5-硝基-6-甲基吡啶
  参考文献：
  名称：

  [EN] PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE
  [FR] INHIBITEURS D'AMIDE D'ACIDE PYRROLOPYRIDINE-2-CARBOXYLIQUE DE LA GLYCOGENE PHOSPHORYLASE

  摘要：

  公开号：

  WO2004104001A3

文献信息

• ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF
  申请人：Soll Mark David

  公开号：US20100125089A1

  公开（公告）日：2010-05-20

  The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives substantially enriched in an enantiomer of formula (I): and compounds of formula (IH) wherein R 3 , R 4 , R 5 , R 6 , R 7 , R 13a , R 13b , R 14a , R 14b , P, Q, V, W, X, Y, Z and a are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.

  本发明涉及一种在式(I)的对映体方面显著富集的新颖芳基唑-2-基-氰基乙基氨基衍生物： 以及式(IH)的化合物 其中R3、R4、R5、R6、R7、R13a、R13b、R14a、R14b、P、Q、V、W、X、Y、Z和a如描述中所定义，以及它们的组合物、其制备方法以及它们作为杀虫剂的用途。
• TRICYCLIC COMPOUNDS AND USE THEREOF
  申请人：Aso Kazuyoshi

  公开号：US20090186879A1

  公开（公告）日：2009-07-23

  There is provided a compound of the formula (I′): wherein x is a nitrogen or CRx, Rx is a hydrogen, etc., R 1 is an optionally substituted hydrocarbon group, etc., R 2 is an optionally substituted hydrocarbon group, etc., ring A is 5- to 8-membered heterocyclic ring, etc., and each of Y 1 , Y 2 and Y 3 is an optionally substituted carbon or a nitrogen, etc.; or a salt thereof or a prodrug thereof, which have CRF receptor antagonistic activity and use thereof.

  提供了一个公式(I′)的化合物：其中x是氮或CRx，Rx是氢等，R1是可选择地取代的碳氢基团等，R2是可选择地取代的碳氢基团等，环A是5-至8-成员的杂环环，等等，Y1、Y2和Y3中的每一个是可选择地取代的碳或氮等；或其盐或前药，具有CRF受体拮抗活性及其用途。
• [EN] HETEROARYL- SUBSTITUTED PYRROLO` 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS<br/>[FR] DERIVES PYRROLO[2,3-B]PYRIDINE A SUBSTITUTION HETEROARYLE UTILISES COMME ANTAGONISTES DES RECEPTEURS DU CRF
  申请人：SB PHARMCO INC

  公开号：WO2004062665A1

  公开（公告）日：2004-07-29

  The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).

  本发明提供了化合物的公式（I），包括立体异构体、前药和其药用可接受的盐或溶剂，以及其制备方法，包含它们的药物组合物，以及它们在治疗由促肾上腺皮质激素释放因子（CRF）介导的疾病中的用途。
• 5-HT1F agonists
  申请人：Eli Lilly and Company

  公开号：US06358972B1

  公开（公告）日：2002-03-19

  The present invention relates to a compound of formula (I): or a pharmaceutical acid addition salt thereof; which is useful for activating 5-HT1f receptors and inhibiting protein extravasation in a mammal.

  本发明涉及以下化合物（I）的化合物或其药用酸盐；该化合物对于激活哺乳动物体内的5-HT1f受体和抑制蛋白外渗具有用处。
• Alkylation of Nitropyridines via Vicarious Nucleophilic Substitution
  作者：Damian Antoniak、Michał Barbasiewicz

  DOI：10.1021/acs.orglett.1c03920

  日期：2022.1.21

  Electrophilic nitropyridines react with sulfonyl-stabilized carbanions to give products of C–H alkylation via vicarious nucleophilic substitution. The process consists of formation of the Meisenheimer-type adduct followed by base-induced β-elimination of the sulfinic acid (e.g., PhSO2H). Mechanistic studies reveal that in the latter step alkyl substituent and adjacent nitro group tend to planarize

  亲电硝基吡啶与磺酰基稳定的碳负离子反应，通过替代亲核取代产生 C-H 烷基化产物。该过程包括形成迈森海默型加合物，然后是碱诱导的亚磺酸（例如，PhSO 2 H）的β-消除。机理研究表明，在后一步中，烷基取代基和相邻的硝基倾向于平面化，以有效稳定苄基阴离子，因此，受阻异丙基碳负离子的加合物由于空间位阻而保持稳定，以消除。

表征谱图